-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $750

Benzinga·07/06/2026 12:52:43
Listen to the news
Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and lowers the price target from $785 to $750.